DL-2-Aminobuttersaeure-betain | 60526-21-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: DL-2-Aminobuttersaeure-betain
• 英文别名: (1-carboxy-propyl)-trimethyl-ammonium betaine；α-Dimethylamino-buttersaeure-methylbetain；(1-Carboxy-propyl)-trimethyl-ammonium-betain；ethyl betaine；2-(trimethylazaniumyl)butanoate
• CAS: 60526-21-8
• 化学式: C₇H₁₅NO₂
• 分子量: 145.202
• InChiKey: JWNWCEAWZGLYTE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  40.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  三甲胺 、 2-溴丁酸乙酯 在 乙醇 作用下， 生成 DL-2-Aminobuttersaeure-betain
  参考文献：
  名称：

  Duvillier, Comptes Rendus Hebdomadaires des Seances de l'Academie des Sciences, 1887, vol. 104, p. 1522

  摘要：

  DOI：

文献信息

• [EN] HAIR COLOR COMPOSITIONS COMPRISING STABLE VIOLET-BLUE TO BLUE IMIDAZOLIUM DYES<br/>[FR] COMPOSITIONS DE COLORATION DES CHEVEUX COMPRENANT DES COLORANTS D'IMIDAZOLIUM STABLES VIOLET-BLEU AU BLEU
  申请人：NOXELL CORP

  公开号：WO2018053034A1

  公开（公告）日：2018-03-22

  Disclosed are hair color compositions comprising novel stable violet-blue to blue imidazolium azo compounds that have a simplified chromophore and high relative solubility in aqueous systems, and that are surprisingly stable under the conditions of use and storage. These compositions are useful for dyeing fibers such as hair and other keratinaceous materials. The compositions can optionally include an oxidant. Also disclosed are methods for dying keratin fibers including human hair using the disclosed hair color compositions. The methods optionally include an ability to alter the electronic charge in situ of the hair color compositions

  揭示了包含新型稳定的紫蓝至蓝色咪唑啉偶氮化合物的染发配方，该化合物具有简化的色团结构，在水系统中具有高相对溶解度，并且在使用和储存条件下具有惊人的稳定性。这些配方适用于染色纤维，如头发和其他角蛋白材料。这些配方可以选择性地包含氧化剂。还揭示了使用所述染发配方染色角蛋白纤维，包括人类头发的方法。这些方法可以选择性地包括在原位改变染发配方的电子电荷的能力。
• [EN] CATIONIC DIRECT DYES<br/>[FR] COLORANTS DIRECTS CATIONIQUES
  申请人：BASF SE

  公开号：WO2016146813A1

  公开（公告）日：2016-09-22

  The invention relates to cationic direct dyes of the formula I (1), wherein m and n are independently from each other 0 or 1, D is an aromatic or a cationic heteroaromatic group, which are further specified, K is an aromatic or heteroaromatic group, E1 and E2 are independently from each other =CH- or =N-, An is an anion and a is a number from 1 to 6 and R1 and R2 are independently from each other and further specified. The compounds show washfastness at hair-dying.

  这项发明涉及公式I（1）的阳离子直接染料，其中m和n分别独立于0或1，D是芳香或阳离子杂芳基，进一步具体说明，K是芳香或杂芳基，E1和E2分别独立于=CH-或=N-，An是阴离子，a是1到6之间的数字，R1和R2分别独立于彼此并进一步具体说明。这些化合物在染发时表现出良好的耐洗性。
• 4-TRIMETHYLAMMONIO-BUTYRATES AS CPT2 INHIBITORS
  申请人：Andjelkovic Mirjana

  公开号：US20090270500A1

  公开（公告）日：2009-10-29

  This invention relates to novel 4-trimethylammoniobutyrates of the formula wherein A 1 , R 1 , m and n are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds inhibit carnitine palmitoyl transferase (CPT) activity, in particular CPT2 activity, and can be used as medicaments.

  该发明涉及一种新型的4-三甲基氨基丁酸盐，其化学式如下，其中A1、R1、m和n的定义见描述和权利要求书，以及其药用盐。这些化合物抑制肉碱棕榈酰基转移酶（CPT）活性，特别是CPT2活性，并可用作药物。
• TOPICAL FORMULATIONS OF TARGETED NITROXIDE AGENTS
  申请人：Falo, JR. Louis D.

  公开号：US20120207687A1

  公开（公告）日：2012-08-16

  A method for preventing or treating skin damage in a radiotherapy subject, comprising topically administering to the subject a composition that includes a therapeutically effective amount at least one targeted nitroxide agent and at least one additional ingredient.

  一种用于预防或治疗放疗受试者皮肤损伤的方法，包括将至少一种靶向亚硝酰胺试剂和至少一种其他成分的治疗有效剂量的组合物局部施用于受试者的皮肤。
• INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER
  申请人：Pauls Heinz W.

  公开号：US20100105900A1

  公开（公告）日：2010-04-29

  A CPT inhibitor compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof: or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject having cancer comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.

  一种CPT抑制剂化合物由结构式(I)或其药学上可接受的盐所代表：或其药学上可接受的盐。一种制药组合物包括由结构式(I)或其药学上可接受的盐所代表的化合物。一种治疗患有癌症的受试者的方法包括向该受试者施用由结构式(I)或其药学上可接受的盐所代表的治疗有效量的化合物。